Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
IAP0971 + Bacillus Calmette-Guerin
- Development stage
- Unknown
- Lead developer
- SUNHO BioPharmaceutical
- Modality
- Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Vaccines & Immunotherapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Intravesical
01
Overview
IAP0971 + Bacillus Calmette-Guerin is an investigational combination therapy designed for high-risk non-muscle invasive bladder cancer (NMIBC), particularly in patients who are unresponsive to or have failed standard BCG treatment. IAP0971 is a fusion protein with dual activity as both an interleukin-15 receptor (IL-15R) agonist and a programmed cell death protein 1 (PD-1) inhibitor, aiming to enhance both innate and adaptive anti-tumor immune responses. Bacillus Calmette-Guerin (BCG) is a live, attenuated strain of *Mycobacterium bovis* widely used as standard intravesical immunotherapy in NMIBC, known to trigger a local immune response in the bladder that targets residual cancer cells. The combination seeks to improve upon outcomes seen with BCG monotherapy by integrating immune checkpoint inhibition and cytokine-mediated immune enhancement.
- Other names
- BCG
02
Targets
IL2RB (IL-2 receptor beta chain)PDCD1 (Programmed cell death protein 1 receptor)
Beyond the preview
Go deeper on IAP0971 + Bacillus Calmette-Guerin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on IAP0971 + Bacillus Calmette-Guerin.